The aim for the second funding period is the thorough evaluation of treatment strategies to suppress graft rejection to improve the outcome of clinical islet transplantation. Specifically, we will concentrate on the reduction of IBMIR through the treatment with potential inhibi-tors or use of genetically modified pig donor islets, we will evaluate a role for the coagula-tion and complement cascades potentially contributing to IBMIR and analyse mechanisms of late graft rejection in the most excellent humanized mouse model available. Importantly, the treatment options will be validated by their potential to revert diabetes in vivo.
For more information:
